aTyr Pharma, Inc.(US:ATYR) Prnewswireยท2025-10-10 02:18Core Viewpoint - A federal class-action lawsuit has been filed against aTyr Pharma, Inc. following an 83% drop in its stock price after its lead drug candidate failed to meet primary endpoints in a Phase 3 trial [1][7]. Group 1: Lawsuit Details - The lawsuit, titled Munguia v. aTyr Pharma Inc., alleges that aTyr and its executives made false and misleading statements regarding the efficacy of its drug Efzofitimod, leading to inflated stock prices [2][5]. - The proposed class includes all investors who acquired aTyr common stock between January 16, 2025, and September 12, 2025 [3]. - The allegations center around aTyr's Phase 3 study, EFZO-FIT, which evaluated Efzofitimod in patients with pulmonary sarcoidosis [3]. Group 2: Company Statements and Market Reaction - Throughout the class period, aTyr executives expressed confidence in the study's design and the drug's potential to reduce steroid dependency [4]. - The lawsuit claims that while making optimistic statements, aTyr was concealing adverse facts about Efzofitimod's efficacy, which constitutes a violation of securities laws [5]. - The negative results from the EFZO-FIT study were disclosed on September 15, 2025, leading to a drastic decline in stock price from $6.03 to $1.02, a drop of 83.2% [6][7]. Group 3: Investigation and Market Opportunity - Hagens Berman is investigating whether aTyr misled investors regarding trial data and the drug's market potential, which was emphasized as a multi-billion-dollar opportunity [8]. - The firm is urging investors who suffered losses or have relevant information to come forward [9].